Author

Linda Chaba

University of California, San FranciscoORCID 0000-0002-4548-2563Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Gregory T. RobertsoniD· 2 shared Nicholas D. WalteriD· 2 shared Radojka M. SavićiD· 2 shared Allison BaumaniD· 1 shared Anna M. UptoniD· 1 shared Belén P. SolansiD· 1 shared David Hermann· 1 shared David L. HoltzmaniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Gregory T. RobertsonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comprehensive preclinical reevaluation of PaBQU and DBQU regimens identifies lesional liability in hard-to-treat forms of tuberculosis

Nicholas D. Walter, Lisa M. Massoudi, Allison Bauman, Noalani D. Benedict, Nathan Peroutka‐Bigus, Michelle E. Ramey, Reem Al Mubarak, Samantha Pauly, Firat Kaya, Linda Chaba, Matthew D. Zimmerman, Debra Flood, David Hermann, Khisimusi Mdluli, David L. Holtzman, , Gregory T. Robertson

This study reevaluates PaBQU and DBQU regimens in mouse models, finding they have lesional liability in complex lesions, which may explain their failure in a human trial.

bioRxiv · Sep 17, 2026 · PreprintMicrobiology

Predicting tuberculosis relapse based on 28-day CFU, RS ratio, and/or drug contribution for novel regimens in the relapsing mouse model

Rob Christiaan van Wijk, Belén P. Solans, Linda Chaba, Sylvie Sordello, Anna M. Upton, Eric L. Nuermberger, Gregory T. Robertson, Nicholas D. Walter, Radojka M. Savić

The paper develops a predictive model to rank tuberculosis regimens by relapse prevention using 28-day CFU and RS ratio data from a relapsing mouse model.

bioRxiv · Jul 30, 2026 · PreprintPharmacology & Toxicology